A broad variety of antigens contribute to the pathogenesis of atherosclerosis: How to neutralize noxious reactions in the host

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 2, 2010, Pages 149-160

  Magrone, T ^a   Jirillo, E ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Advanced glycated end products; Bacteria; Endothelial cells; Glycated proteins; Heat shock proteins; Immune cells; Lipopolysaccharides; Toll like receptors

Indexed keywords

ANTIBIOTIC AGENT; ANTIGEN; APOLIPOPROTEIN D; AZITHROMYCIN; CYCLOSPORIN; GAMMA INTERFERON; GLYCOSYLATED HEMOGLOBIN; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; LIPOPROTEIN; LOCOSTATIN; LOW DENSITY LIPOPROTEIN; PEXELIZUMAB; RAPAMYCIN; ROXITHROMYCIN; SIMVASTATIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHLAMYDIAL PNEUMONIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIET THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOST; HUMAN; IMMUNOTHERAPY; NONHUMAN; OXIDATION; PATHOGENESIS; PORPHYROMONAS GINGIVALIS; SMOKING;

EID: 77954061510     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010791213083     Document Type: Article

References (175)

1. Schiraldi, M. and Monestier, M. (2009) How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity. Trends Immunol., 30(10), 502-509.
2. Kivity, S.; Agmon-Levin, N.; Blanck, M. and Shoenfeld, Y. (2009) Infections and autoimmunity. Friends or foes? Trends Immunol., 30(8), 409-414.
3. Davenport, M.P.; Belz, G.T. and Ribeiro, R.M. (2009) The rage between infection and immunity: how do pathogenic set the pace? Trends Immunol., 30(2), 61-64.
4. Raz, E. (2010) Mucosal immunity: aliment and ailments. Mucosal Immunol., 31(1), 4-7.
5. Soehnein, O. (2009) An element defense: How neutrophils shape the immune response. Trends Immunol., 30(11), 511-512.
6. Panda, A.; Arjona, A.; Sapey, E.; Bai, F.; Fikrig, E.; Montgomery, R.R.; Lord, J.M. and Shaw, A. (2009) Human innate immunosenescence: causes and consequences for immunity in old page. Trends Immunol., 30(7), 325-333.
7. Lekstrom-Himes, J.A. and Gallin, J.I. (2009) Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med., 343(23), 1703-1714.
8. Datta, S. and Sarvetnik, N. (2009) Lymphocyte proliferation in immune-mediated diseases. Trend Immunol., 30(9), 430-438.
9. Jameson, S.C. (2002) Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol., 2(8), 547-556.
10. Randolph, G.J. (2001) Dendritic cell migration to lymph nodes: cytokines, chemokines and lipid mediators. Semin. Immunol., 13(5), 267-274.
11. Scheffold, A.; Murphy, K.M. and Höfer T. (2007) Competition for cytokines: T(reg) cells take all. Nat. Immunol., 8(12), 1285-1287.
12. Mc Hugar, R.S. and Shevach, E.M. (2002) Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol., 168(12), 5979-5983.
13. Palmer, D.C. and Restifo, N.P. (2009) Suppressors of leukocyte signaling (SOCS) in T cell differentiation, maturation and function. Trends Immunol., 30(12), 592-602.
14. Honda, K. and Takeda, K. (2009) Regulatory mechanisms of immune responses to intestinal bacteria. Mucosal Immunol., 2(3), 187-196.
15. Neish, A.S. (2009) Microbes in gastrointestinal health and disease gastroenterology commensal bacteria shape intestinal immune system development. Gastroenteology, 136(1), 65-80.
16. Libby, P.; Ridker, P.M.; Hansson, G.K. and Leducq Transatlantic Network on Atherothrombosis. (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol., 54(23), 2129-2138.
17. Weber, C.; Zernecke, A. and Libby, P. (2008) The multifaced contribution of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol., 8(10), 802-815.
18. Hassan, G.S.; Mehri, Y. and Mourad, W.M. (2009) CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol., 30(4), 165-172.
19. Loppnow, H.; Werdan, K. and Buerke, M. (2008) Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun., 14(2), 63-87.
20. Slevin, M.; Krupinski, J. and Badimon, L. (2009) Controlling the angiogenic switch in developing atherosclerotic plaques: Possible targets for therapeutic intervention. J. Angiogen. Res., 1, 4.
21. Coombes, B.K. and Mahony, J.B. (1999) Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect. Immun., 67(6), 2909-2915.
22. Lehr, H.A.; Sagban, T.A.; Ihling, C.; Zahringer, U.; Hungerer, K.D.; Blumrich, M.; Reifenberg, K. and Bhakdi S. (2001) Immunopathogenesis of atherosclerosis; endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation, 104(8), 914-920.
23. Karrer, U.; Althage, A.; Odermatt, B.; Roberts, C.W.; Korsmeyer, S.J.; Miyawaki, S.; Hengartner, H. and Zinkernagel, R.M. (1997) On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11 (-)/-) mutant mice. J. Exp. Med., 185(12), 2157-2170.
24. Blank, M. and Shoenfeld, Y. (2009) Infections and autoimmunity-friends or foes? Trends Immunol., 30(8), 409-414.
25. Xu, Q. (2003) Infections, heat shock proteins, and atherosclerosis. Curr. Opin. Cardiol., 18(4), 245-252.
26. Horwitz, M.S.; Bradley, L.M.; Harbertson, J.; Krahl, T.; Lee, J. and Sarvetnick, N. (1998) Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med., 4(7), 781-785.
27. Netea, M.G.; Kullberg, B.J.; Galama, J.M.; Stalenhoef, A.F.; Dinarello, C.A. and van der Meer, J.W. (2002) Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur. J. Immunol., 32(4), 1188-1195.
28. Leitinger, N. (2003) Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Opin. Lipidol., 14(5), 421-430.
29. Zhou, X.; Paulsson, G.; Stemme, S. and Hansson, G.K. (1998) Hypercholesterolemia is associated with T helper (Th)1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest., 101(8), 1717-1725.
30. Stitt, A.W.; He, C.; Friedman, S.; Scher, L.; Rossi, P.; Ong, L.; Founds, H.; Li, Y.M.; Bucala, R. and Vlassara, H. (1997) Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med., 3(9), 617-627.
31. Vardavas, C.I. and Panagiotakos, D.B. (2009) The causal relationship between passive smoking and inflammation on the development of cardiovascular disease: a review of evidence. Inflammation Allergy Drug Targets, 8(5), 328-333.
32. Hektoen, L. (1896) The vascular changes of tuberculous meningitis, especially the tuberculous endarterities. J. Exp. Med., 1(1), 112-163.
33. nd ed.; J.B. Lippincott, Philadelphia, Pa.
34. Osler, W. (1908) Diseases of the arteries, in Osler, W. and MacCrae, T. Ed, Modern medicine: its theory and practice in original contributions by American and foreign authors. Lea and Febiger, Philadelphia, Pa 1908; pp. 426-447.
35. Saikku, P.; Leinonen, M.; Mattila, K.; Ekman, M.R.; Nieminen, M.S.; Makela, P.H.; Huttenen, J.K. and Valtonen, V. (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infection. Lancet, 2(8618), 983-986.
36. Camm, A.J. and Fox, K.M. (2000) Chlamydia pneumoniae (and other infective agents) in atherosclerosis and acute coronary syndromes. How good is the evidence? Eur. Heart J., 21(13) 1046-1051.
37. Farsak, B.; Yildirir, A.; Akyon, Y.; Pinar, A.; Boke, E.; Kes, S. and Tokgözoǧlu, L. (2000) Detection of Chlamydia pneumoniae and Helicobacter pylory DNA in human atherosclerotic plaques by PCR. J. Clin. Microbiol., 38(12), 4408-4411.
38. Smieja, M.; Mahony, J.; Petrich, A.; Boman, J. and Chernesky, M. (2002) Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect. Dis., 2, 21.
39. Ngeh, J. and Gupta, S. (2000) C. pneumoniae and atherosclerosis: causal or coincidental link? ASM News, 66(12), 733-737.
40. Chiu, B.; Viira, E.; Tucker, W. and Fong, I.W. (1997) Chlamydia pneumoniae, citomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation, 96(7), 2144-2148.
41. Vink, A.; Poppen, M.; Schoneveld, A.H.; Roholl, P.J.; de Kleijn, D.P.; Borst, C. and Pasterkamp, G. (2001) Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation, 103(12), 1613-1617.
42. Kern, J.M.; Maas, V. and Maass, M. (2009) Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signaling cascades. Thromb. Haemost., 102(6), 1064-1070.
43. Ameriso, S.F.; Fridman, E.A.; Leiguarda, R.C. and Sevlever, G.E. (2001) Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke, 32(2), 385-391.
44. Danesh, J. and Peto, R. (1998) Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ, 316(7138), 1130-1132.
45. Pietroiusti, A.; Diomedi, M.; Silvestrini, M.; Cupini, L.M.; Luzzi, I.; Gomez-Miguel, M.J.; Bergamaschi, A.; Magrini, A.; Carrabs, T.; Vellini, M. and Galante, A. (2002) Cytotoxin-associated gene-A-positive Helicobacter pylori strain are associated with atherosclerotic stroke. Circulation, 106(5), 580-584.
46. Mayr, M.; Kiechl, S.; Mendall, M.A.; Willeit, J.; Wick, G. and Xu, Q. (2003) Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylory strains: Prospective results from the Bruneck study. Stroke, 34(3), 610-615.
47. Gibson, F.C. III and Genco, C.A. (2007) Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: disparate diseases with commonalities in pathogenesis through TLRs. Curr. Pharm. Des., 13(36), 3165-3675.
48. Zhou, Y.F.; Leon, M.B.; Waclawiw, M.A.; Popma, J.J.; Yu, Z.X.; Finkel, T. and Epstein, S.E. (1996) Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med., 335(9), 624-630.
49. Yonemitsu, Y.; Nakagawa, K.; Tanaka, S.; Mori, R.; Sugimachi, K. and Sueishi, K. (1996) In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: possible pathogenic role in sustained chronic inflammatory reaction. Lab. Invest., 74(4), 723-736.
50. Zhu, J.; Quyyumi, A.A.; Norman, J.E.; Csako, G.; Waclawiw, M.A.; Shearer, G.M. and Epstein. S.E. (2000) Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am. J. Cardiol., 85(2), 140-146.
51. Moazed, T.C.; Campbell, L.A.; Rosenfeld, M.E.; Grayston, J.T. and Kuo, C.C. (1999) Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J. Infect. Dis., 180(1), 238-241.
52. Caligiuri, G.; Rottenberg, M.; Nicoletti, A.; Wigzell, H. and Hansson, G.K. (2001) Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation, 103(23), 2834-2838.
53. Xu, X.H.; Shah, P.K.; Faure, E.; Equils, O.; Thomas, L.; Fishebein, M.C.; Luthringer, D.; Xu, X.P.; Rajavashisth, T.B.; Yano, J.; Kaul, S. and Arditi, M. (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation, 104(25), 3103-3108.
54. Edfeldt, K.; Swedenborg, J.; Hansson, G.K. and Yan, Z.Q. (2002) Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation, 105(10), 1158-1161.
55. Zeuke, S.; Ulmer, A.J.; Kusumoto, S.; Katus, H.A. and Heine, H. (2002) TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc. Res., 56(1), 126-134.
56. Lajunen, T.; Vikatmaa, P.; Bloigu, A.; Ikonen, T.; Lepantalo, M.; Pussinen, P.J.; Saikku, P. and Leinonen, M. (2008) Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index patients with cardiovascular disease. Innate Immun., 14(6), 375-382.
57. Kallio, K.A.; Buhlin, K.; Jauhiainen. M.; Keva, R.; Tuomainen, A.M.; Klinge, B.; Gustafsson, A. and Pussinen, P.J. (2008) Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun., 14(4), 247-253.
58. Wiedermann, C.J.; Kiechl, S.; Duzendorfer, S.; Schratzberger, P.; Egger, G.; Oberhollenzer, F. and Willeit, J. (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J. Am. Coll. Cardiol., 34(7), 1975-1981.
59. Kiechl, S.; Egger, G.; Mayr, M.; Wiedermann, C.J.; Bonora, E.; Oberhollenzer, F.; Muggeo, M.; Xu, Q.; Wick, G.; Poewe, W. and Willeit, J. (2001) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation, 103(8), 1064-1070.
60. Arbour, N.C.; Lorenz, E.; Schutte, B.C.; Zabner, J.; Kline, J.N.; Jones, M.; Frees, K.; Watt, J.L. and Scwartz, D.A. (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet, 25(25), 187-191.
61. Kiechl, S.; Lorenz, E.; Reindl, M.; Wiedermann, C.J.; Oberhollenzer, F.; Bonora, E.; Willeit, J. and Schwartz, D.A. (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med., 347(3), 185-192.
62. Amezianen, N.; Beillat, T.; Verpillat, P.; Chollet-Martin, S.; Aumont, M.; Seknadji, P.; Lamotte, M.; Lebret, D.; Ollivier, V. and de Prost, D. (2003) Association of the Toll-like receptor 4 gene Asp299Gly polymorphisms with acute coronary events. Arterioscler. Thromb. Vasc. Biol., 23(12), e61-64.
63. Boekholdt, S.M.; Agema, W.R.; Peters, R.J.; Zwinderman, A.H.; van der Wall, E.; Reitsma, P.H.; Kastelein, J.J. and Jukema, J.W. (2003) Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation, 107(19), 2415-2421.
64. Ishida, B.Y.; Blanche, P.J.; Nichols, A.V.; Yashar, M. and Paigen, B. (1991) Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J. Lipid. Res., 32(4), 559-568.
65. Shi, W.; Haberland, M.E.; Jien, M.L.; Shih, D.M. and Lusis, A.J. (2000) Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation, 102(1), 75-81.
66. Michelsen, K.S.; Wong, M.H.; Shah, P.K.; Zhang, W.; Yano, J.; Doherty, T.M., Akira, S.; Rajavashisth T.B. and Arditi, M. (2004) Lack of Toll like receptor 4 or myeloid differentiation reduced atherosclerosis and alter plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA, 101(29), 10679-10684.
67. Netea, M.G.; Hijmans, A.; van Wissen, S.; Smilde, T.J.; Trip, M.D.; Kullberg, B.J.; de Boo, T.; Van der Meer, J.W.; Kastelein, J.J. and Stalenhoef, A.F. (2004) Toll-like receptor-4 Ap299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest., 34(2), 94-99.
68. Yang, I.A.; Holloway, J.W. and Ye, S. (2003) TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis, 170(1), 187-190.
69. Edfeldt, K.; Bennet, A.M.; Eriksson, P.; Frostegard, J.; Wiman, B.; Hamsten, A.; Hansson, G.K.; de Faire, U. and Yan, Z.Q. (2004) Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur. Heart. J., 25(16), 1447-1453.
70. Jackson, S.P. and Calkin, A.C. (2007) The clot thickens-oxidized lipids and thrombosis. Nat. Med., 13(9), 1015-1016.
71. Hulsmans, M. and Holvoet, P. (2009) The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell. Mol. Med., [Epub ahead of print].
72. Binder, C.J.; Hörkkö, S.; Dewan, A.; Chang, M.K.; Kieu, E.P.; Goodyear, C.S.; Shaw, P.X.; Palinski, W.; Witztum, J.L. and Silverman, G.J. (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med., 9(6), 736-743.
73. Walton, K.A.; Hsieh, X.; Gharavi, N.; Wang, S.; Wang, G.; Yeh, M.; Cole, A.L. and Berliner, J.A. (2003) Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem., 278(29), 29661-29666.
74. Miller, Y.I.; Viriyakosol, S.; Binder, C.J.; Feramisco, J.R.; Kirkland, T.N. and Witztum, J.L. (2003) Minimal modified LDL binds to CD14 induces macrophage spreading via TLR4/MD-2 and inhibits phagocytosis of apoptotic cells. J. Biol. Chem., 278(3), 1561-1568.
75. Walton, K.A.; Cole, A.L.; Yeh, M.; Subbanagounder, G.; Krutzik, S.R.; Modlin, R.L.; Lucas, R.M.; Nakai, J.; Smart, E.J.; Vora, D.K. and Berliner, J.A. (2003) Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol., 23(7), 1197-1203.
76. Navarra, T.; Del Turco, S.; Berti, J.S. and Basta, G. (2009) The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J. Atheroscler. Thromb., [Epub ahead of print].
77. Kol, A.; Sukhova, G.K.; Lichtman, A.H. and Libby, P. (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation, 98(4), 300-307.
78. Bulut, Y.; Faure, E.; Thomas, L.; Karahashi, H.; Michelsen, K.S.; Equils, O.; Morrison, S.G.; Morrison, R.P. and Arditi, M. (2002) Chlamydial heat shock protein 60 activates macrophages and endo thelial cells through Toll-like receptor 4 and MD2 in a Myd 88-dependent pathway. J. Immunol., 168(3), 1435-1440.
79. Sasu, S.; LaVerda, D.; Qureshi, N.; Golenbock, D.T. and Beasley, D. (2001) Chlamydia pneumoniae and Chlamydial heat shock pro tein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ. Res., 89(3), 244-250.
80. Kalayoglu, M.V.; Hoerneman, B.; LaVerda, D.; Morrison, S.G.; Morrison, R.P. and Byrne, G.I. (1999) Cellular oxidation of lowdensity lipoprotein by Chlamydia pneumoniae. J. Infect. Dis., 180(3), 780-790.
81. Maillard, L.C. (1912) Action des acides amines sur les sucres: formation des melanoiddines par voie mèthodique. C.R. Acad. Sci., 154, 66-68.
82. Yaylayan, V.A. and Huyghues-Despointes, A. (1994) Chemistry of Amadori rearrangement production: analysis, synthesis, kinetics, reactions, and spectroscopic properties. Crit. Rev. Food Sci. Nutr., 34(4), 321-369.
83. Ahmed, N. (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract., 67(1), 3-21.
84. Price, C.L. and Knight, S.C. (2007) Advanced glycation: a novel outlook on atherosclerosis. Curr. Pharm. Des., 13(36), 3681-3687.
85. Schmidt, A.M.; Yan, S.D.; Yan, S.F. and Stern, D.M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 108(7), 949-955.
86. Westwood, M.E.; McLellan, A.C. and Thornalley, P.J. (1994) Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin: competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. J. Biol. Chem., 269(51), 32293-32298.
87. Goldin, A.; Beckman, J.A.; Schmidt, A.M. and Creager, M.A. (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114(6), 597-605.
88. Price, C.L.; Sharp, P.S.; North, M.E.; Rainbow, S.J. and Knight, S.C. (2004) Advanced glycation end products modulate the matura tion and function of peripheral blood dendritic cells. Diabetes, 53(6), 1452-1458.
89. Yilmaz, A.; Reiss, C.; Tantawi, O.; Weng, A.; Stumpf, C.; Raaz, D.; Ludwig, J.; Berger, T.; Steinkasserer, A.; Daniel, W.G. and Garlichs, C.D. (2004). HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis, 172(1), 85-93.
90. Andrassy, M.; Igwe, J.; Autschbach, F.; Volz, C.; Remppis, A.; Neurath, M.F.; Schleicher, E.; Humpert, P.M.; Wendt, T.; Liliensiek, B.; Morcos, M.; Schiekofer, S.; Thiele, K.; Chen, J.; Kientsch-Engel, R.; Schimdt, A.M.; Stremmel, W.; Stern, D.M.; Katus, H.A.; Nawroth, P.P. and Bierhaus, A. (2006) Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am. J. Pathol., 169(4), 1223-1237.
91. Tahara, Y. and Shima, K. (1995) Kinetics of HbA1c glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care, 18(4), 440-447.
92. Park, S.; Barrett-Connor, E.; Wingard, D.L.; Shan, J. and Edelstein, S. (1996) GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care, 19(5), 450-456.
93. Khaw, K.T.; Wareham, N.; Luben, R.; Bingham, S.; Oakes, S.; Welch, A. and Day, N. (2001) Glucated haemoglobin, diabetes, and mortality in men in Norfolk cohort european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ, 322(7277), 15-18.
94. Stitt, A.W.; He, C.; Friedman, S.; Scher, L.; Rossi, P.; Ong, L.; Founds, H.; Li, Y.M.; Bucala, R. and Vlassara, H. (1997) Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med., 3(9), 617-627.
95. Witztum, J.L.; Mahoney, E.M.; Branks, M.J.; Fisher, M.; Elam, R. and Steinberg D. (1982) Nonenzymatic glucosylation of low-density lipoproteins alters its biological activity. Diabetes, 31(4 Pt 1), 283-291.
96. Triau, J.E.; Arbetter, J. and Schaefer, E.J. (1986) Impaired hepatocyte binding, uptake and degradation of glucosylated low-density lipoproteins. Biochem. Biophys. Acta, 887(3), 359-365.
97. Matsui, H.; Okumura, K.; Toki, Y. and Hayakawa, T. (1999) Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level. Diabetes Care, 22(7), 1220-1221.
98. La Belle, M. and Krauss, R.M. (1990) Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass pattern. J. Lipid. Res., 31(9), 1577-1588.
99. Misciagna, G.; Logroscino, G.; De Michele G.; Guerra V.; Cisternino, A.M.; Caruso, M.G. and Trevisan, M. (2006) Glycated apolipoprotein B and myocardial infarction. Nutr. Metab. Cardiovasc. Dis. 17(1), 6-12.
100. Gupta, S.; Leatham, E.W.; Carrington, D.; Mendall, M.A.; Kaski, J.C. and Camm, A.J. (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation, 96(2), 404-407.
101. Gurfinkel, E.; Bozovich, G.; Da Roca, A.; Beck, E. and Mautner, B. (1997) Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet, 350(9075), 404-407.
102. Cannon, C.P.; Braunwald, E.; McCabe, C.H.; Grayston, J.J.; Muhlestein, B.; Giugliano, R.P.; Cairns, R. and Skene, A.M. (2005) Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med., 352(16), 1646-1654.
103. Cercek, B.; Shah, P.K.; Noc, M.; Zahger, D.; Zeymer, U.; Matetzky, S.; Maurer, G. and Mahrer, P. (2003) Effect of short term treatment with azithromycin on recurrent ischaemic events in patients with Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial. Lancet, 361(9360), 809-813.
104. Grayston, J.T.; Kronmal, R.A.; Jackson, L.A.; Parisi, A.F.; Muhlestein, J.B.; Cohen, J.D.; Rogers, W.J.; Crouse, J.R.; Borrowdale, S.L.; Schron, E. and Knirsch, C. (2005) Azythromycin for the secondary prevention of coronary events. N. Engl. J. Med., 352(16), 1637-1645.
105. O'Connor, C.M.; Dunne, M.W.; Pfeffer, M.A.; Muhlestein, J.B.; Yao, L.; Gupta, S.; Benner, R.J.; Fisher, M.R. and Cook, T.D. (2003) Azythromycin for the secondary prevention of coronary heart disease events: The WIZARD study: a randomized controlled trial. JAMA, 290(11), 1459-1466.
106. Vainas, T.; Sayed, S.; Bruggeman, C.A. and Stassen, F.R. (2009) Exploring the role of Chlamydia pneumoniae in cardiovascular disease: a narrative review. Drugs Today, 45(Suppl. B), 165-172.
107. Muhlestein, J.B.; Anderson, J.L.; Hammond, E.H.; Zhao, L.; Trehan, S.; Schwobe, E.P. and Carlquist, J.F. (1998) Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation, 97(7), 633-636.
108. Rothstein, N.M.; Quinn, T.C.; Madico, G.; Gaydos, C.A. and Lowenstein, C.J. (2001) Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J. Infect. Dis., 183(2), 232-238.
109. Elizalde, J.I.; Pérez-Pujol, S.; Heras, M.; Sionis, A.; Casanovas, N.; Martorell, T.; Lozano, M.; González, J.; Escolar, G.; Sanz, G. and Piqué, J.M. (2004) Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter, 9(6), 681-689.
110. Brown, D.L.; Desai, K.K.; Vakili, B.A.; Nounech, C.; Lee, H.M. and Golub, L.M. (2004) Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol., 24(4), 733-738.
111. Johnson, R.N.; Metcalf, P.A. and Bayer H.R. (1983) Fructosamine: a new approach to the estimation of serum control of serum glycosyl protein. An index of diabetic control. Clin. Chim. Acta., 127(1), 87-85.
112. Jenkins, D.J.; Wolever, T.M.; Collier, G.R; Ocana, A.; Rao, A.V.; Buckley, G.; Lam, Y.; Mayer, A. and Thompson, L.U. (1987) Metabolic effects of low-glycemic-index diet. Am. J. Clin. Nutr., 46(6), 968-975.
113. Ryle, A.J.; Davie, S.; Gould, B.J. and Yudkin, J.S. (1990) A study of the effect of diet on glycosylated haemoglobin and albumin levels and glucose tolerance in normal subjects. Diabet. Med., 7(10), 865-870.
114. Boeingh, H.; Weisgerber, V.M.; Jeckel, A.; Rose, H.J. and Kroke, A. (2000) Association between glycated hemoglobin and diet and other lifestyle factors in a nondiabetic population: cross-sectional evaluation of data from Postdam cohort of the European Prospective Investigation into Cancer and Nutrition Study. Am. J. Clin. Nutr., 71(5), 1115-1122.
115. Trevisan, M.; Krogh, V.; Freudenheim, J.; Blake, A.; Muti, P.; Panico, S.; Farinaro, E.; Mancini, M.; Menotti, A. and Ricci, G. (1990) Consumption of olive oil, butter and vegetable oil and coronary heart disease risk factors. The Research Group ATS-RF2 of the Italian National Research Council. JAMA, 263(5), 688-692.
116. Davie, S.J.; Gould, B. and Yudkin, S.S. (1992) Effect of vitamin C on glycosylation of proteins. Diabetes, 41(2), 167-173.
117. Shoff, S.M.; Mares-Perlman, J.A.; Cruickshanks, K.J.; Klein, R.; Klein, B.E. and Ritter, L.L. (1993) Glycosylatied hemoglobin concentrations and vitamin E, vitamin C, and beta-carotene in the in diabetic old adults. Am. J. Clin. Nutr., 58(3), 412-416.
118. Binder, C.J.; Horkko, S.; Dewan, A.; Chang, M.K.; Kieu, E.P.; Goodyear, C.S.; Shaw, P.X.; Palinski, W.; Witztum, J.L. and Silverman, G.J. (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med., 9(6), 736-743.
119. Ameli, S.; Hultgardh-Nilsson, A.; Regnstrom, J.; Calara, F.; Yano, J.; Cercek, B.; Shah, P.K. and Nilsson, J. (1996) Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol., 16(8), 1074-1079.
120. Hansson H.K. and Libby, P. (2006) The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 6(7), 508-519.
121. Wick, G.; Schett, G.; Amberger, A.; Kleindiest, R. and Xu, Q. (1995) Is atherosclerosis an immunologically mediated disease? Immunol. Today, 16(1), 27-33.
122. Maron, R.; Sukhova, G.; Faria, A.M.; Hoffmann, E.; Mach, F.; Libby, P. and Weiner, H.L. (2002) Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoproteins receptor-deficient mice. Circulation, 106(13), 1708-1715
123. Gallo, R.; Padurean, A.; Jayaraman, T.; Marx, S.; Roque, M.; Adelman, S.; Chesebro, J.; Fallon, J.; Fuster, V.; Marks, A. and Badimon, J.J. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 99(16), 2164-2170.
124. Marx, S.O. and Marks, A.R. (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation, 104(8) 852-855.
125. Takemoto, M. and Liao, J.K. (2001) Pleiotropic effects of 3-hydroxy-3methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol., 21(11), 1712-1719.
126. Beri, A.; Sural, N. and Mahajan, S.B. (2009) Non-atheroprotective effects of statins: a systematic review. Am. J. Cardiovasc. Drugs, 9(6), 361-370.
127. Kwak, B.; Mulhaupt, F.; Myit, S. and Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med., 6(12), 1399-1402.
128. Menoret, T.A.; McAleer, J.P.; Ngoi, S.M.; Ray, S.; Eddy, N.A.; Fenteany, G.; Lee, S.J.; Rossi, R.J.; Mukherji, J.B.; Allen, D.L; Chakraborty, N.G. and Vella, A.T. (2009) The oxazolidinone derivative locostatin induces cytokine appeasement. J. Immunol., 183(11), 7489-7496.
129. Steffens, S.; Burger, F.; Pelli, G.; Dean, Y.; Elson, G.; Kosco-Vilbois, M.; Chatenoud, L. and Mach, F. (2006) Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation, 114(18), 1977-1984.
130. Mach, F.; Schonbeck, U.; Sukhova, G.K.; Atkinson, E and Libby, P. (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 394(6689), 200-203.
131. Vakeva, A.P.; Agah, A.; Rollins, S.A.; Matis, L.A.; Li, L. and Stahl, G.L. (1998) Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of terminal complement components and inhibition by anti-C5 therapy. Circulation, 97(22), 2259-2267.
132. Haverich, A.; Sherman, S.K.; Levy, J.H.; Chen, J.C.; Carrier, M.; Taylor, K.M.; Van de Werf, F.; Newman, M.F.; Adams, P.X.; Todaro, T.G.; van der Laan, M. and Verrier, E.D. (2006) Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann. Thorac. Surg., 82(2), 486-492.
133. Schmidt, C. (2006) Toll-like receptor therapies compete to reduce side effects. Nat. Biotechnol., 24(3), 230-231.
134. Hawkins, L.D.; Christ, W.H. and Rossignol D.P. (2004) Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr. Top. Med. Chem., 4(11), 1147-1161.
135. Niesser, A.; Steiner, S.; Speidl, W.S.; Pleiner, J.; Seidinger, D.; Maurer, G.; Goronzy, J.J.; Weyand, C.M.; Kopp, C.W.; Huber, K.; Wolzt, M. and Wojta, J. (2006) Simvastain suppresses endotoxininduced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis, 189(2), 408-413.
136. Branèn, L.; Hovgaard, L.; Nitulescu, M.; Bengtsson, E.; Nilsson, J. and Jovinge, S. (2004) Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol., 24 (11), 2137-2142.
137. Rizzello, V.; Liuzzo, G.; Brugaletta, S.; Rebuzzi, A.; Biasucci, L.M. and Crea, F. (2006) Modulation of CD4 (+) CD28 null T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina. Circulation, 113(19), 2272-2277.
138. Bozkurt. B.; Torre-Amione, G.; Warren, M.S.; Whitmore, J.; Soran, O.Z.; Feldman, A.M. and Mann, D.L. (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation, 103(8), 1044-1047.
139. Irace, C.; Mancuso, G.; Fiaschi, E.; Madia, A.; Sesti, G. and Gnasso, A. (2004) Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis., 177(1), 113-118.
140. Lee, S.H.; Park, D.W.; Park, S.C.; Park, Y.K.; Hong, S.Y.; Kim, J.R.; Lee, C.H. and Baek, S.H. (2009) Calcium-independent phospholipase A2beta-Akt signaling is involved in lipopolysaccharide-induced NADPH oxidase 1 expression and foam cell formation. J. Immunol., 183(11), 7497-7504.
141. Xie, S.; Nie, R. and Wang, J. (2009) Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability. J. Postgrad. Med., 55(4), 284-286.
142. Murphy, A.J. and Woollard, K.J. (2009) High density lipoprotein-a potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol., [Epub ahead of print].
143. Belyakov, I.M. and Ahlers, J.D. (2009) What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol., 183(11), 6883-6892
144. Lavelle, E.C.; Murphis, C.; O'Neill, L.A. and Creagh, E.M. (2010) The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol., 33(1), 17-28.
145. Liu, Y.; Chen, G.Y. and Zheng, P. (2009) CD24-Siglec G/10 discriminates danger from pathogen-associated molecular patterns. Trends Immunol., 30(12), 557-561.
146. Liu, Y. and Zheng, P. (2007) CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol., 28(7), 315-320.
147. Eberl, M.; Hintz, M.; Reichenberg, A.; Kollas, A.K.; Wiesner, J. and Jomaa, H. (2003) Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett., 544(1-3), 4-10.
148. Eberl, M. and Moser, B. (2009) Monocytes and gammadelta T cells: close encounters in microbial infection. Trends Immunol., 30(12), 562-568.
149. Jirillo, E.; Candore, G.; Magrone, T. and Caruso, C. (2008) A scientific approach to anti-ageing therapies: state of the art. Curr. Pharm. Des., 14(26), 2637-2642.
150. Candore, G.; Caruso, C.; Jirillo, E.; Magrone, T. and Vasto, S. (2010) Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr. Pharm. Des., 16(6), 584-596.
151. Perdomo, G. and Dong, H.H. (2009) Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging. Aging, 1(1), 17-27.
152. Marian, M. and Sacks G. (2009) Micronutrients and older adults. Nutr. Clin. Pract., 24(2), 179-195.
153. Hoyles, L. and Vulevic, J. (2008) Diet, immunity and functional foods. Adv. Exp. Med. Biol., 635, 79-92.
154. Magrone, T.; Panaro, M.A.; Jirillo, E. and Covelli, V. (2008) Molecular effects elicited in vitro by red wine on human healthy peripheral blood mononuclear cells: potential therapeutical application of polyphenols to diet-related chronic diseases. Curr. Pharm. Des., 14(26), 2758-2766.
155. Jirillo, F.; Jirillo, E. and Magrone T. (2010) Donkey's and goat's milk comsuption and benefits to human health with special reference to the inflammatory status. Curr. Pharm. Des., 16(6), 864-869.
156. Jirillo, F.; Martemucci, G.; D'Alessandro, A.G.; Panaro, M.A.; Superbo, M.; Cianciulli, A.; Jirillo, E. and Magrone T. (2010) Ability of goat milk to modulate healthy human peripheral blood lymphomonocyte and polymorphonuclear cell function: in vitro effects and clinical implications. Curr. Pharm. Des., 16(6), 870-876.
157. Amati, L.; Marzulli, G.; Martulli, M.; Pugliese, V.; Caruso, C.; Candore, G.; Vasto, S. and Jirillo, E. (2010) Administration of a synbiotic to free-living elderly and evaluation of serum cytokines. Curr. Pharm. Des., 16(6), 854-858.
158. Cherubini, A.; Ruggiero, C. and Lattanzio, F. (2009) Polyunsaturated fatty acids and human health: a critical appraisal of the evidence. Curr. Pharm. Des., 15(36), 4085-4086.
159. Calzolari, I.; Fumagalli, S.; Marchionni, N. and Di Bari, M. (2009) Polyunsaturated fatty acids and cardiovascular disease. Curr. Pharm. Des., 15(36), 4094-4102.
160. Abbatecola, A.M.; Evans, W. and Paolisso, G. (2009) PUFA supplements and type 2 diabetes in the elderly. Curr. Pharm. Des., 15(36), 4126-4134.
161. Ruggiero, C.; Lattanzio, F.; Lauretani, F.; Gasperini, B.; Andres-Lacueva, C. and Cherubini, A. (2009) Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr. Pharm. Des., 15(36), 4135-4148.
162. Lefebvre, P.; Chinetti, G.; Fruchart, J.C. and Staels, B. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest., 116(3), 571-580.
163. Davidson, M.H. (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol., 98(4A), 27i-33i.
164. Bassaganya-Riera, J.; Reynolds, K.; Martino-Catt, S.; Cui, Y.; Hennighausen, L.; Gonzalez, F.; Rohrer, J.; Benninghoff, A.U. and Hontecillas, R. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology, 127(3), 777-791.
165. Torres, N.; Torre-Villalvazo, I. and Tovar, A.R. (2006) Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders. J. Nutr. Biochem., 17(6), 365-373.
166. Rimando, A.M.; Nagmani, R.; Feller, D.R. and Yokoyama, W. (2005) Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem., 53(9), 3403-3407.
167. Panadero, M.I.; González, M.C.; Herrera, E. and Bocos, C. (2009) Factors modulating fibrates response: therapeutic implications and alternative strategies. Endocr. Metab. Immune Disord. Drug Targets, 9(3), 219-236.
168. Aggarwal, S. and Gurney, A.L. (2002) IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol., 71(1), 1-8.
169. Langris, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.; Kastelein, R.A. and Cua, D.J. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med., 201(2), 233-240.
170. Erbel, C.; Chen, L.; Bea, F.; Wangler, S.; Celik, S.; Lasitschka, F.; Wang, Y.; Böckler, D.; Katus, H.A. and Dengler, T.J. (2009) Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J. Immunol., 183(12), 8167-8175.
171. Peck, A. and Mellins, E.D. (2010) Precarious balance: Th17 cells in host defense. Infect. Immun., 78(1), 32-38.
172. Baetta, R. and Corsini, A. (2009) Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives. Atherosclerosis, [Epub ahead of print].
173. Tabas I. (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol., 10(1), 36-46.
174. Zernecke, A. and Weber, C. (2010) Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc. Res., [Epub ahead of print].
175. Surmi, B.K. and Hasty, A.H. (2010) The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul. Pharmacol., 52(1-2), 27-36.